Neurocrine Biosciences
Clinical trials sponsored by Neurocrine Biosciences, explained in plain language.
-
New drug aims to keep schizophrenia at bay
Disease control Not yet recruitingThis study is testing whether an investigational drug called NBI-1117568 can help prevent schizophrenia symptoms from coming back in adults whose symptoms are currently stable. The trial will involve about 560 adults with schizophrenia who have responded well to initial treatment…
Phase: PHASE3 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Apr 04, 2026 05:21 UTC
-
New hope for uncontrollable movements
Disease control Not yet recruitingThis study is testing whether an experimental drug called NBI-1065890 can reduce involuntary movements in adults with tardive dyskinesia. About 100 participants with moderate to severe symptoms will receive either the drug or a placebo for 8 weeks. Researchers will measure change…
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for schizophrenia patients in crisis
Disease control Not yet recruitingThis study is testing an investigational drug called NBI-1117570 for adults who are hospitalized due to a severe worsening of schizophrenia symptoms. It will compare the drug to a placebo to see if it helps reduce symptoms and is safe. The goal is to find a new treatment option t…
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC